TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Davies, Gerald F ^a   Berg, Arnie ^a   Postnikoff, Spike D L ^a   Wilson, Heather L ^c   Arnason, Terra G ^b   Kusalik, Anthony ^a   Harkness, Troy A A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; HISTONE DEACETYLASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MULTIDRUG RESISTANCE PROTEIN 1; MYC PROTEIN; OXYGEN; PROTEIN KINASE P60; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR 1; UNCLASSIFIED DRUG; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL GROWTH; CELL HYPOXIA; CELL LEVEL; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENE CLUSTER; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR EVOLUTION; NONHUMAN; OXYGEN CONCENTRATION; RAT; ANIMAL; DRUG RESISTANCE; GENETICS; MCF 7 CELL LINE; METABOLISM; PHYSIOLOGY; TUMOR CELL CULTURE;

ANIMALS; CELL HYPOXIA; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOPROTEINS; MCF-7 CELLS; TUMOR CELLS, CULTURED;

EID: 84900300482     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084611     Document Type: Article

References (74)

1. Zahreddine H, Borden KL (2013) Mechanisms and insights into drug resistance in cancer. Front Pharmacol 4: 28.
2. Ruf W (2012) Tissue factor and cancer. Thromb Res 130: S84-87.
3. Donati MB, Lorenzet R (2012) Thrombosis and cancer: 40 years of research. Thromb Res 129: 348-352.
4. Noble S, Pasi J (2010) Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 102: S2-9.
5. Castelli R, Ferrari B, Cortelezzi A, Guariglia A (2010) Thromboembolic complications in malignant haematological disorders. Curr Vasc Pharmacol 8: 482-494.
6. Liu Y, Jiang P, Capkova K, Xue D, Ye L, et al. (2011) Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res 71: 6492-6502.
7. Nigro CL, Wang H, McHugh A, Lattanzio L, Matin R, et al. (2013) Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma. J Invest Dermatol 133: 1278-1285.
8. Lechtenberg BC, Freund SM, Huntington JA (2012) An ensemble view of thrombin allostery. Biol Chem 393: 889-898.
9. Borsig L (2010) Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb Res 125: S66-71.
10. Lee CJ, Ansell JE (2011) Direct thrombin inhibitors. Br J Clin Pharmacol 72: 581-592.
11. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
12. Conley SJ, Wicha MS (2012) Antiangiogenic agents: fueling cancer's hypoxic roots. Cell Cycle 11: 1265-1266.
13. Maroney SA, Ellery PE, Mast AE (2010) Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb Res 125: S52-56.
14. Adams M (2012) Tissue factor pathway inhibitor: new insights into an old inhibitor. Semin Thromb Hemost 38: 129-134.
15. Iversen N, Lindahl AK, Abildgaard U (1998) Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 102: 889-895. (Pubitemid 28410516)
16. Gandemer V, Rio AG, de Tayrac M, Sibut V, Mottier SL, et al. (2007) Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia. BMC Genomics 2007, 8:385.
17. Kurer MA (2007) Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep 34: 221-224. (Pubitemid 47624283)
18. Iversen N, Lindahl AK, Abildgaard U (2002) Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Thromb Res 105: 33-36. (Pubitemid 34178305)
19. Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W (2010) Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost 103: 198-204.
20. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, et al. (1981) Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 245: 831-835. (Pubitemid 11135890)
21. Piro O, Broze GJ Jr (2005) Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost 3: 2677-2683.
22. Stavik B, Skretting G, Olstad OK, Sletten M, Dehli Vigeland M, et al. (2012) TFPI Alpha and Beta Regulate mRNAs and microRNAs Involved in Cancer Biology and in the Immune System in Breast Cancer Cells. PLoS One 7: e47184.
23. Liu Y, Stack SM, Lakka SS, Khan AJ, Woodley DT, et al. (1999) Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Arch Biochem Biophys 370: 112-118. (Pubitemid 29476957)
24. Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, et al. (2003) Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 63: 5381-5389. (Pubitemid 37139855)
25. Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, et al. (2007) The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 33: 643-652. (Pubitemid 350157007)
26. Girard TJ (2007) A factor X-TFPI hybrid protein inhibits B16 melanoma metastatic growth in mice. Thromb Res 121: 427-428.
27. Lin YF, Zhang N, Guo HS, Kong DS, Jiang T, et al. (2007) Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway. Apoptosis 12: 2163-2173. (Pubitemid 350077250)
28. Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N (2010) Overexpression of both TFPIα and TFPIβ induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. Mol Carcinog 49: 951-963.
29. Stavik B, Skretting G, Aasheim HC, Tinholt M, Zernichow L, et al. (2011) Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. BMC Cancer 11: 357.
30. Henriquez S, Calderon C, Quezada M, Oliva B, Bravo ML, et al. (2011) Progesterone utilizes distinct membrane pools of tissue factor to increase coagulation and invasion and these effects are inhibited by TFPI. J Cell Physiol 226: 3278-3285.
31. Davies GF, Juurlink BH, Harkness TAA (2009) Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Des Devel Ther 3: 79-88.
32. Davies GF, Roesler WJ, Juurlink BH, Harkness TAA (2005) Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leuk Lymphoma 46: 1199-1206. (Pubitemid 41087027)
33. Davies GF, Ross AR, Arnason TG, Juurlink BH, Harkness TAA (2010) Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Lett 288: 236-250.
34. Bharadwaj LA, Davies GF, Xavier IJ, Ovsenek N (2002) l-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1 alpha) in H9c2 cardiomyoblasts. Pharmacol Res 45: 175-181. (Pubitemid 35418358)
35. Blazejczyk M, Miron M, Nadon R (2007) FlexArray: A statistical data analysis software for gene expression microarrays. Genome Quebec, Montreal, Canada, Available: http://genomequebec.mcgill.ca/FlexArray.
36. Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548. (Pubitemid 351911712)
37. Lin SM, Du P, Huber W, Kibbe WA (2008) Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 36: e11.
38. de Jonge HJ, Fehrmann RS, de Bont ES, Hofstra RM, Gerbens F, et al. (2007) Evidence based selection of housekeeping genes. PLoS One 2: e898.
39. Glozak MA, Seto E (2007) Histone deacetylases and cancer. Oncogene 26: 5420-5432. (Pubitemid 47255924)
40. Mah LJ, El-Osta A, Karagiannis TC (2010) GammaH2AX as a molecular marker of aging and disease. Epigenetics 5: 129-136.
41. Rapisarda A, Melillo G (2012) Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 9: 378-390.
42. Bottsford-Miller JN, Coleman RL, Sood AK (2012) Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 30: 4026-4034.
43. Ward C, Langdon SP, Mullen P, Harris AL, Harrison DJ, et al. (2013) New strategies for targeting the hypoxic tumour microenvironment in breast cancer. Cancer Treat Rev 39: 171-179.
44. Semenza GL (2011) Oxygen sensing, homeostasis, and disease. N Engl J Med 365: 537-547.
45. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33: 207-214.
46. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, et al. (2001) HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15: 2445-2453. (Pubitemid 33063172)
47. Garnier D, Magnus N, D'Asti E, Hashemi M, Meehan B, et al. (2012) Genetic pathways linking hemostasis and cancer. Thromb Res 129: S22-29.
48. Naldini A, Filippi I, Ardinghi C, Silini A, Giavazzi R, et al. (2009) Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. Eur J Cancer 45: 454-460.
49. Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8: 519-530.
50. Liu L, Ning X, Sun L, Zhang H, Shi Y, et al. (2008) Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 99: 121-128. (Pubitemid 350239040)
51. Kwon SJ, Song JJ, Lee YJ (2005) Signal pathway of hypoxia-inducible factor-1alpha phosphorylation and its interaction with von Hippel-Lindau tumor suppressor protein during ischemia in MiaPaCa-2 pancreatic cancer cells. Clin Cancer Res 11: 7607-7613. (Pubitemid 41611600)
52. Toffoli S, Feron O, Raes M, Michiels C (2007) Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1alpha. Biochim Biophys Acta 1773: 1558-1571. (Pubitemid 47498610)
53. Hervouet E, Cartron PF, Jouvenot M, Delage-Mourroux R (2013) Epigenetic regulation of estrogen signaling in breast cancer. Epigenetics 8: 237-245.
54. Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, et al. (2009) Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 69: 6223-6231.
55. McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, et al. (2012) Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res 72: 548-559.
56. Waldmann T, Schneider R (2013) Targeting histone modifications- epigenetics in cancer. Curr Opin Cell Biol 25: 184-189.
57. Tatum D, Li S (2011) Evidence that the histone methyltransferase Dot1 mediates global genomic repair by methylating histone H3 on lysine 79. J Biol Chem 286: 17530-17535.
58. Luebben WR, Sharma N, Nyborg JK (2010) Nucleosome eviction and activated transcription require p300 acetylation of histone H3 lysine 14. Proc Natl Acad Sci USA 107: 19254-19259.
59. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, et al. (2010) Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 29: 5957-5968.
60. Jurkin J, Zupkovitz G, Lagger S, Grausenburger R, Hagelkruys A, et al. (2011) Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 10: 406-412.
61. Segre CV, Chiocca S (2011) Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. J Biomed Biotechnol 2011: 690848.
62. Khan DH, He S, Yu J, Winter S, Cao W, et al. (2013) Protein kinase CK2 regulates the dimerization of histone deacetylase (HDAC) 1 and HDAC2 during mitosis. J Biol Chem 288: 16518-16528.
63. Maciejczyk A (2013) New prognostic factors in breast cancer. Adv Clin Exp Med 22: 5-15.
64. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582-1584. (Pubitemid 24308973)
65. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, et al. (2000) Tissue factor pathway inhibitor binds to platelet thrombospondin-1. J Biol Chem 275: 31715-31721.
66. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR (2013) Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 171: 36-45.
67. Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9: 653-660.
68. Marlar RA, Griffin JH (1980) Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest 66: 1186-1189. (Pubitemid 11233824)
69. Spek CA, Arruda VR (2012) PL-15 The protein C pathway in cancer metastasis. Thromb Res 129: S80-84.
70. Schuepbach RA, Velez K, Riewald M (2011) Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain. Blood 117: 6338-6346.
71. Henkin J, Volpert OV (2011) Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Expert Opin Ther Targets 15: 1369-1386.
72. Volpert OV, Dameron KM, Bouck N (1997) Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene 14: 1495-1502. (Pubitemid 27182439)
73. Suzuki H, Tomida A, Tsuruo T (2001) Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 20: 5779-5788. (Pubitemid 32937947)
74. Stünkel W, Campbell RM (2011) Sirtuin 1 (SIRT1): the misunderstood HDAC. J. Biomol. Screen 16: 1153-1169.